Status:
TERMINATED
ChemoFx® PRO - A Post-Market Data Collection Study
Lead Sponsor:
Precision Therapeutics
Conditions:
Ovarian Cancer
Fallopian Tube Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study will collect patient demographic, oncology history, and physician reported outcome information following the initial round of chemotherapy received after a commercial ChemoFx® Final Report ...
Detailed Description
The traditional treatment course for new cases of many cancers is cytoreductive surgery followed by chemotherapy. Unfortunately, despite high initial response rates to treatment, the majority of patie...
Eligibility Criteria
Inclusion
- Patient has been diagnosed with a solid tumor malignancy and their physician has received a final report for ChemoFx® after August 1, 2006
- Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
- Patient must be at least 18 years of age
- Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.
Exclusion
- Patient pathology shows benign pathology for sample submitted
- Patient is not indicated to receive chemotherapy for their disease
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
2756 Patients enrolled
Trial Details
Trial ID
NCT00669422
Start Date
October 1 2006
End Date
October 1 2012
Last Update
October 5 2012
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
University of South Alabama
Mobile, Alabama, United States, 36688
3
University of California San Francisco
San Francisco, California, United States, 94115
4
Women's Cancer Center of Southern California
Sherman Oaks, California, United States, 91403